J&J kicks off final study of single-shot Covid-19 vaccine in 60,000 volunteers | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Friday
July 11, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
FRIDAY, JULY 11, 2025
J&J kicks off final study of single-shot Covid-19 vaccine in 60,000 volunteers

Coronavirus chronicle

Reuters
23 September, 2020, 04:50 pm
Last modified: 23 September, 2020, 04:57 pm

Related News

  • US limits use of J&J's Covid vaccine on blood clot risks
  • J&J says its single dose protects against breakthrough Covid-19 for up to 6 months
  • J&J, Sinopharm, Sputnik V shots weaker against Omicron, study shows
  • EU regulator backs J&J Covid-19 booster dose for adults
  • Healthcare giant Johnson & Johnson to split into two companies

J&J kicks off final study of single-shot Covid-19 vaccine in 60,000 volunteers

Rival vaccines from Moderna Inc, Pfizer Inc and AstraZeneca all require two shots separated by several weeks, which make them much more difficult to administer

Reuters
23 September, 2020, 04:50 pm
Last modified: 23 September, 2020, 04:57 pm
FILE PHOTO: The company logo for Johnson & Johnson is displayed on a screen to celebrate the 75th anniversary of the company's listing at the New York Stock Exchange (NYSE) in New York, US, September 17, 2019. REUTERS/Brendan McDermid/File Photo
FILE PHOTO: The company logo for Johnson & Johnson is displayed on a screen to celebrate the 75th anniversary of the company's listing at the New York Stock Exchange (NYSE) in New York, US, September 17, 2019. REUTERS/Brendan McDermid/File Photo

Johnson & Johnson on Wednesday kicked off a final 60,000-person trial of a single-shot Covid-19 vaccine that potentially would simplify distribution of millions of doses compared with leading rivals using two doses.

The company expects results of the Phase III trial by year end or early next year, Dr Paul Stoffels, J&J's chief scientific officer, said in a joint press conference with officials from the National Institutes of Health and the Trump administration.

Rival vaccines from Moderna Inc, Pfizer Inc and AstraZeneca all require two shots separated by several weeks, which make them much more difficult to administer.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

"The benefits of a single-shot vaccine are potentially profound in terms of mass immunization campaigns and global pandemic control," Dr Dan Barouch, a Harvard vaccine researcher who helped design J&J's Covid-19 vaccine, said in a telephone interview.

Stoffels said J&J would publish a detailed study protocol for its phase 3 trial Wednesday on the company's website, joining the three other vaccine makers that have made these study plans available in recent weeks after calls for increased transparency in the trials.

Stoffels said J&J started the phase 3 trial after seeing positive results in its phase 1/2 trial in the United States and Belgium. The company plans to release those results imminently.

Stoffels said the safety and level of protection in the study were on par with what was seen in the company's animal studies, and said the results showed a single dose could offer sufficient protection "for a long time."

J&J's late-stage trial will use as many as 215 sites in the United States, South Africa, Argentina, Brazil, Chile, Colombia, Mexico and Peru. The company plans to manufacture as many as 1 billion doses in 2021, and more after that, Stoffels said.

The goal of the trial is to test whether the vaccine can prevent moderate to severe Covid-19 after a single dose, but it will also look to see if the vaccine can prevent serious disease requiring medical intervention and whether it can prevent milder cases of the virus.

Stoffels predicts it will take six weeks to two months to enroll the trial, and said the company hopes to get an answer on whether the vaccine works "around the end of the year or early next year."

It is not clear how fast the company could get regulatory approval, but J&J plans to manufacture doses before approval, so it could start distribution quickly.

The trial will be overseen by an independent Data and Safety Monitoring Board (DSMB) that will review vaccine safety and effectiveness. In the press conference, Dr Francis Collins, director of the National Institutes of Health, said all three of the vaccines being organized and supported by the federal government's Operation Warp Speed - J&J's, Moderna's and AstraZeneca's - share a common DSMB. Pfizer is running its own trial and has a separate DSMB, Collins said.

J&J's trial is designed to test for a vaccine that is 60 percenteffective. In the study protocol, that could be determined after 154 people became infected with the virus. Stoffels said the company will start counting cases of Covid-19 infections within the study population 15 days after individuals are vaccinated.

The DSMB will take its first look at the vaccine's efficacy after 20 people have become infected.

Collins said the DSMB does not include any federal employees and is made up of "very highly experienced" scientists and statistical experts.

"Until they are convinced that there's something there that looks promising, nothing is unblinded and sent to the FDA. So everybody should feel pretty reassured," Collins said. His comments follow concerns government scientists may be pressured to rush the vaccine testing process to boost US President Donald Trump's re-election bid. 

J&J Covid-19 Vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Bangladesh's delegation, led by Commerce Adviser Sk Bashir Uddin, began high-level negotiations with USTR Ambassador Jamieson Greer at 9pm Bangladesh time on Thursday (10 July). Photo: Collected from the Facebook handle of Golam Mortoza, Press Minister at the Bangladesh Embassy in the US
    No need to worry as US tariff talks ongoing: Fouzul tells biz leaders
  • Commerce Adviser Sk Bashir Uddin met USTR Ambassador Jamieson Greer at the USTR office in Washington, DC on 10 July 2025. Photo: CA Press Wing
    35% tariff: Commerce adviser meets US trade representative in Washington
  • Economist Abul Barkat; Photo: Courtesy
    Economist Abul Barkat arrested in graft case

MOST VIEWED

  • Graphics: TBS
    BB raises startup fund limit, drops upper age barrier
  • Workers pack undergarments at the packing section of a garment factory in Ashulia, on the outskirts of Dhaka, Bangladesh, April 19, 2025. Photo: REUTERS/Fatima Tuj Johora
    After US tariffs, jobs hang by a thread in Bangladesh's garments sector
  • Photo: Mohammad Minhaj Uddin/TBS
    SSC, equivalent results: Pass rate drops to 68.45%, GPA-5 also declines
  • File photo of containers at Chattogram port/TBS
    US buyers push Bangladeshi exporters to share extra tariff costs
  • Govt vehicle purchase, foreign trip, new building construction banned: Finance ministry
    Govt vehicle purchase, foreign trip, new building construction banned: Finance ministry
  • Students sit for SSC exam at Motijheel Girls' High School on 10 April 2025. Photo: Mehedi Hasan/TBS
    SSC exam results out: Here's how you can check online and via SMS

Related News

  • US limits use of J&J's Covid vaccine on blood clot risks
  • J&J says its single dose protects against breakthrough Covid-19 for up to 6 months
  • J&J, Sinopharm, Sputnik V shots weaker against Omicron, study shows
  • EU regulator backs J&J Covid-19 booster dose for adults
  • Healthcare giant Johnson & Johnson to split into two companies

Features

Photo: Collected/BBC

What Hitler’s tariff policy misfire can teach the modern world

11h | The Big Picture
Illustration: TBS

Behind closed doors: Why women in Bangladesh stay in abusive marriages

14h | Panorama
Purbachl’s 144-acre Sal forest is an essential part of the area’s biodiversity. Within it, 128 species of plants and 74 species of animals — many of them endangered — have been identified. Photo: Syed Zakir Hossain/TBS

A forest saved: Inside the restoration of Purbachal's last Sal grove

14h | Panorama
Photo: Rajib Dhar/TBS

11 July 2024: Riot vehicles, water cannons hit the streets as police crack down on protesters

7h | Panorama

More Videos from TBS

'Hypocrisy' will not continue, Iran tells IAEA

'Hypocrisy' will not continue, Iran tells IAEA

9h | TBS World
OpenAI to release web browser in challenge to Google Chrome

OpenAI to release web browser in challenge to Google Chrome

9h | TBS World
Will the title 'Honorable and Excellency' be abolished?

Will the title 'Honorable and Excellency' be abolished?

10h | TBS Today
July Declaration must be constitutionally recognized: Akhtar Hossain

July Declaration must be constitutionally recognized: Akhtar Hossain

10h | TBS Today
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net